Denali and Sanofi Provide Update on its RIPK1 Program

 Denali and Sanofi Provide Update on its RIPK1 Program

Sanofi Signs an Agreement with Google to Develop Virtual Innovation Lab for Transforming Healthcare Services

Shots:

  • Denali reported the results of P-Ib studies of DNL747 in AD and ALS and provides an update on its broad RIPK1 program including DNL788 and DNL758. The P-Ib studies has met its safety endpoints in patients with ALS and AD, further dose escalation to achieve higher levels of target inhibition may be limited by preclinical chronic safety data
  • The two companies will pause the clinical studies of DNL747 and focus on accelerating development of DNL788 in neurological indications, with a plan to initiate its clinical testing by early 2021
  • Sanofi has completed P-I study of DNL758 in healthy volunteer and is planning further clinical studies in multiple indications following the P-I data

Click here to read full press release/ article | Ref: Buinesswire | Image: Pharmaworld

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post